The Autism Science Foundation and the NIH Fund Study of Promising Treatment for Autism Subtypes

Source: 
Newswise
Date Published: 
August 26, 2013
Abstract: 

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received grants from the National Institutes of Health and the Autism Science Foundation to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for subtypes of autism. Clinical Director at the Seaver Autism Center, Dr. Alex Kolevzon, says, "IGF-1 has the potential to be effective in treating Phelan-McDermid Syndrome and other types of autism spectrum disorder. We are very pleased that the NIH and the Autism Science Foundation have recognized this by providing us funding to continue our work in bringing this medication to our patients.”

Hear more from Dr. Alex Kolevzon on the ASF YouTube channel here.